Lifecome Biochemistry Co Ltd (002868) - Total Assets
Based on the latest financial reports, Lifecome Biochemistry Co Ltd (002868) holds total assets worth CN¥773.72 Million CNY (≈ $113.22 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Lifecome Biochemistry Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Lifecome Biochemistry Co Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Lifecome Biochemistry Co Ltd's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of Lifecome Biochemistry Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Lifecome Biochemistry Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Lifecome Biochemistry Co Ltd's total assets of CN¥773.72 Million consist of 27.7% current assets and 72.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.4% |
| Accounts Receivable | CN¥48.08 Million | 6.4% |
| Inventory | CN¥95.48 Million | 12.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥21.08 Million | 2.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Lifecome Biochemistry Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Lifecome Biochemistry Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lifecome Biochemistry Co Ltd's current assets represent 27.7% of total assets in 2025, a decrease from 28.4% in 2012.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2025, up from 4.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 12.8% of total assets.
Lifecome Biochemistry Co Ltd Competitors by Total Assets
Key competitors of Lifecome Biochemistry Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Lifecome Biochemistry Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 0.16 | 1.05 |
| Quick Ratio | 0.39 | 0.08 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-176.82 Million | CN¥-1.02 Billion | CN¥9.69 Million |
Lifecome Biochemistry Co Ltd - Advanced Valuation Insights
This section examines the relationship between Lifecome Biochemistry Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 56.21 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | -49.8% |
| Total Assets | CN¥748.71 Million |
| Market Capitalization | $564.69 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lifecome Biochemistry Co Ltd's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lifecome Biochemistry Co Ltd's assets decreased by 49.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lifecome Biochemistry Co Ltd (2012–2025)
The table below shows the annual total assets of Lifecome Biochemistry Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥748.71 Million ≈ $109.56 Million |
-49.81% |
| 2024-12-31 | CN¥1.49 Billion ≈ $218.28 Million |
-24.09% |
| 2023-12-31 | CN¥1.97 Billion ≈ $287.54 Million |
+58.49% |
| 2022-12-31 | CN¥1.24 Billion ≈ $181.43 Million |
-1.47% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.14 Million |
+29.40% |
| 2020-12-31 | CN¥972.50 Million ≈ $142.31 Million |
-3.72% |
| 2019-12-31 | CN¥1.01 Billion ≈ $147.80 Million |
+25.88% |
| 2018-12-31 | CN¥802.42 Million ≈ $117.42 Million |
+6.11% |
| 2017-12-31 | CN¥756.25 Million ≈ $110.66 Million |
+104.03% |
| 2016-12-31 | CN¥370.66 Million ≈ $54.24 Million |
-5.57% |
| 2015-12-31 | CN¥392.52 Million ≈ $57.44 Million |
+0.62% |
| 2014-12-31 | CN¥390.09 Million ≈ $57.08 Million |
-1.46% |
| 2013-12-31 | CN¥395.88 Million ≈ $57.93 Million |
+6.60% |
| 2012-12-31 | CN¥371.37 Million ≈ $54.34 Million |
-- |
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. engages in research, development, production, and sales of veterinary drugs in China. It offers probiotics and green microbial functional additives; biopesticides, biofertilizers, and pesticide formulations; and food additives. The company was founded in 2003 and is based in Pucheng, China.